The collaboration aims to accelerate development and scale to GMP manufacturing
Synthetic biology company Asimov has partnered with CDMO Lotte Biologics to accelerate cell line development and scaling to GMP manufacturing.
“We’re delighted to be directly integrating with Lotte Biologics’ established manufacturing capabilities, meaning our customers can now transition seamlessly from cell line development to large-scale GMP production, and drastically shorten their development cycles,” said Asimov co-founder and CEO Alec Nielsen.
The collaboration aims to increase the efficiency and speed of development by combining Asimov’s CHO Edge cell line development platform and Lotte Biologics’ large-scale manufacturing services.
The CHO Edge system generates stable cell lines with high titer, enabling optimisation of the expression vector and bioreactor processes across various biologics modalities.
To accommodate diverse biologics modalities, the CHO Edge system incorporates a GS knock-out CHO host, a hyperactive transposase, advanced computational tools and a library of over 1,000 characterized genetic elements.
The partnership follows a scale-up of the CHO Edge system, completed by Lotte Biologics.
“By combining Asimov’s technology with Lotte Biologics’ manufacturing expertise, we will not only deliver unparalleled services to our customers but also drive innovation in the biopharmaceutical industry,” said Lotte Biologics’ CEO James Park.
Last year, Asimov’s CHO Edge system was integrated Rev Opsis’ RO-104 platform, optimising the development of therapies for retinal vascular diseases.
